Angiotensin II and atherosclerosis: Relevance for renal disease

Contributions to Nephrology

Volumn 135, Issue , 2001, Pages 235-249

  Galle, Jan ^a   Quaschning, Thomas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; LIPOPROTEIN;

ANIMAL; ARTERIOSCLEROSIS; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

ANGIOTENSIN II; ANIMALS; ARTERIOSCLEROSIS; BIOPSY, NEEDLE; HUMANS; KIDNEY DISEASES; LIPOPROTEINS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0035538373     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000060170     Document Type: Article

References (111)

1. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD: Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998;98:800-807.
2. Ihara M, Urata H, Kinoshita A, Suzumiya J, Sasaguri M, Kikuchi M, Ideishi M, Arakawa K: Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999;33:1399-1405.
3. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996;94:2756-2767.
4. Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T: Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens 1999;17:547-553.
5. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques - Potential implications for inflammation and plaque instability. Circulation 2000;101:1372-1378.
6. Arakawa K, Maruta H: Ability of kallikrein to generate angiotensin II-like pressor substance and a proposed 'kinin-tensin enzyme system'. Nature 1980;288:705-706.
7. Tonnesen MG, Klempner MS, Austen KF, Wintroub BU: Identification of a human neutrophil angiotension II-generating protease as cathepsin G. J Clin Invest 1982;69:25-30.
8. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
9. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM: Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
10. Bell L, Madri JA: Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990;137:7-12.
11. Grafe M, Auch Schwelk W, Zakrzewicz A, Regitz Zagrosek V, Bartsch P, Graf K, Loebe M, Gaehtgens P, Fleck E: Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin. Circ Res 1997;81:804-811.
12. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-651.
13. Hahn AW, Jonas U, Bühler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994;347:178-180.
14. Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, Saruta T: Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991;9:17-22.
15. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
16. phox in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 2000;279:H2234-H2240.
17. - formation. Br J Pharmacol 2000;131:667-672.
18. Pueyo ME, Arnal JF, Rami J, Michel JB: Angiotensin II stimulates the production of NO and peroxynitrite in endothelial cells. Am J Physiol Cell Physiol 1998;274:C214-C220.
19. Zhang H, Schmeisser A, Garlichs CD, Plötze K, Damme U, Mügge A, Daniel WG: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: Role of membrane-bound NADH-/NADPH- oxidases. Cardiovasc Res 1999;44:215-222.
20. Sohn H-Y, Gloe T, Keller M, Schoenafinger K, Pohl U: Sensitive superoxide detection in vascular cells by the new chemiluminescence dye L-012. J Vasc Res 1999;36:456-464.
21. Kip1: Role in angiotensin II-mediated hypertrophy of proximal tubular cells. J Am Soc Nephrol 2000;11:1387-1397.
22. Pagano PJ, Clark JK, Cifuentes Pagano ME, Clark SM, Callis GM, Quinn MT: Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: Enhancement by angiotensin II. Proc Natl Acad Sci USA 1997;94:14483-14488.
23. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase - Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
24. Görlach A, Brandes RP, Nguyen K, Amidi M, Dehghani F, Busse R: A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000;87:26-32.
25. Heinloth A, Heermeier K, Raff U, Wanner C, Galle J: Stimulation of NADPH Oxidase by oxidized LDL induces proliferation of human vascular endothelial cells. J Am Soc Nephrol 2000;11:1819-1825.
26. Bayraktutan U, Blayney L, Shah AM: Molecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cells. Arterioscler Thromb Vasc Biol 2000;20:1903-1911.
27. Ichikawa I, Kiyama S, Yoshioka T: Renal antioxidant enzymes: their regulation and function. Kidney Int 1994;45:1-9.
28. Klahr S: Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997;23:140-143.
29. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. Am J Physiol Cell Physiol 1996;271:C1424-C1437.
30. Gwinner W, Landmesser U, Brandes RP, Kubat B, Plasger J, Eberhard O, Koch KM, Olbricht CJ: Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997;8:1722-1731.
31. Harrison DG, Ohara Y: Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: Implications for impaired vasomotion. Am J Cardiol 1995;75:75B-81B.
32. Rubanyi GM, Vanhoutte PM: Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
33. Pryor WA, Squadrito GL: The chemistry of peroxynitrite: A product from the reaction of nitric oxide with superoxide. Am J Physiol 1995;268:L699-L722.
34. Loscalzo J: Nitric oxide and vascular disease. N Engl J Med 1995;333:251-253.
35. Galle J, Schneider R, Heinloth A, Wanner C, Galle PR, Conzelmann E, Dimmeler S, Heermeier K: Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta - Role of oxidative stress. Kidney Int 1999;55:1450-1461.
36. Dimmeler S, Haendeler J, Galle J, Zeiher AM: Oxidized low density lipoprotein induces apoptosis of human endothelial cells by activation of CPP32-like proteases: A mechanistic clue to the 'response to injury' hypothesis. Circulation 1997;95:1760-1763.
37. Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M: Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci USA 1991;88:10045-10048.
38. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation - Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
39. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG: Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 1997;95:588-593.
40. Heitzer T, Wenzel U, Hink U, Krollner D, Skatchkov M, Stahl RAK, Macharzina R, Bräsen JH, Meinertz T, Münzel T: Increased NAD(P)H oxidase-mediated superoxide production in renovascular hypertension: Evidence for an involvement of protein kinase C. Kidney Int 1999;55:252-260.
41. Dijkhorst-Oei LT, Stroes ESG, Koomans HA, Rabelink TJ: Acute simultaneous stimulation of nitric oxide and oxygen radicals by angiotensin II in humans in vivo. J Cardiovasc Pharmacol 1999;33:420-424.
42. Ushio Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK: p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-23321.
43. Kip1 induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int 1998;54:1923-1933.
44. Jaimes EA, Galceran JM, Raij L: Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775-784.
45. Aberg G, Ferrer P: Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990;15:S65-S72.
46. Chobanian AV, Haudenschild CC, Nickerson C, Hope S: Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1992;20:473-477.
47. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, Keidar S: The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res 1999;44:579-587.
48. Hope S, Brecher P, Chobanian AV: Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 1999;12:28-34.
49. Wiemer G, Scholkens BA, Becker RHA, Busse R: Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
50. Mancini GBJ, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard ACG, Pepine CJ, Pitt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease - The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-265.
51. Cashin Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS: Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. Quinapril Ischemic Event Trial. Am J Cardiol 1999;83:43-47.
52. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
53. MacMahon S, Sharpe N, Gamble G, Clague A, Mhurchu CN, Clark T, Hart H, Scott J, White H: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000;36:438-443.
54. Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak V, Dzavik V, Taylor D, Yokoyama S, Montague TJ, SCAT Investigators: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis - The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-1754.
55. Nickenig G, Sachinidis A, Michaelsen F, Böhm M, Seewald S, Vetter H: Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997;95:473-478.
56. 1-receptor expression. Am J Physiol Heart Circ Physiol 1997;272:H2701-H2707.
57. Morawietz H, Rueckschloss U, Niemann B, Galle J, Hakim K, Zerkowski H-R, Sawamura T, Holtz J, Duerrschmidt N, Zerkowski HR: Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low density lipoprotein. Circulation 1999;100:899-902.
58. Ohara Y, Peterson TE, Harrison DG: Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2546-2551.
59. Mügge A, Brandes RP, Böger RH, Dwenger A, Bode-Böger S, Kienke S, Frölich JC, Lichtlen PR: Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardivasc Pharmacol 1994;24:994-998.
60. - and renin release in juxtaglomerular cells. Kidney Int 1997;51:253-260.
61. Galle J, Schneider R, Winner B, Lehmann-Bodem C, Schinzel R, Münch G, Conzelmann E, Wanner C: Glyc-oxidized LDL impair endothelial function more potently than oxidized LDL: Role of enhanced oxidative stress. Atherosclerosis 1998;138:65-77.
62. Galle J, Bengen J, Schollmeyer P, Wanner C: Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a) - Role of oxygen-derived radicals. Circulation 1995;92:1582-1589.
63. Hansen PR, Kharazmi AK, Jauhiainen M, Ehnholm C: Induction of free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest 1994;24:497-499.
64. Sharma P, Reddy K, Franki N, Sanwal V, Sankaran R, Ahuja TS, Gibbons N, Mattana J, Singhal PC: Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Kidney Int 1996;50:1604-1611.
65. Hein TW, Kuo L: LDLs impair vasomotor function of the coronary microcirculation - Role of superoxide anions. Circ Res 1998;83:404-414.
66. Harada-Shiba M, Kinoshita M, Kamido H, Shimokado K: Oxidized low density lipoprotein induces apoptosis in cultured human umbilical vein endothelial cells by common and unique mechanisms. J Biol Chem 1998;273:9681-9687.
67. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witzum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-1095.
68. Ylä-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
69. Sato H, Suzuki S, Ueno M, Shimada H, Karasawa R, Nishi S-I, Arakawa M: Localization of apolipoprotein(a) and B-100 in various renal diseases. Kidney Int 1993;43:430-435.
70. Lee HS, Kim YS: Identification of oxidized low density lipoprotein in human renal biopsies. Kidney Int 1998;54:848-856.
71. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-945.
72. Anonymous: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-1863.
73. Diamond JR, Anderson S: Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 1990;137:1323-1332.
74. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW: Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension 1995;25:207-213.
75. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G: Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990;85:541-549.
76. Lafayette RA, Mayer G, Park SK, Meyer TW: Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766-771.
77. Tanaka R, Sugihara K, Tatematsu A, Fogo A: Internephron heterogeneity of growth factors and sclerosis - Modulation of platelet-derived growth factor by angiotensin II. Kidney Int 1995;47:131-139.
78. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, et al: Contribution of renal angiotensin II type I receptor to gene expressions in hypertension-induced renal injury. Kidney Int 1994;46:1346-1358.
79. Kohara K, Mikami H, Okuda N, Higaki J, Ogihara T: Angiotensin blockade and the progression of renal damage in the spontaneously hypertensive rat. Hypertension 1993;21:975-979.
80. Ziai F, Ots M, Provoost AP, Troy JL, Rennke HG, Brenner BM, Mackenzie, HS: The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int Suppl 1996;57:S132-S136.
81. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz SM: Renal injury from angiotensin II-mediated hypertension. Hypertension 1992;19:464-474.
82. Harris RC, Cheng HF: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 1996;4(suppl 1):2-7.
83. Anderson S: Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab 1998;24:406-411.
84. Klahr S, Morrissey J: Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998;31:171-176.
85. Wolf G: Angiotensin II: a pivotal factor in the progression of renal diseases. Nephrol Dial Transplant 1999;14(suppl 1):42-44.
86. Radeke HH, Resch K: The inflammatory function of renal glomerular mesangial cells and their interaction with the cellular immune system. Clin Invest 1992;70:825-842.
87. Greiber S, Münzel T, Kastner S, Müller B, Schollmeyer P, Pavenstadt H: NAD(P)H oxidase activity in cultured human podocytes: Effects of adenosine triphosphate. Kidney Int 1998;53:654-663.
88. Cui XL, Douglas JG: Arachidonic acid activates c-jun N-terminal kinase through NADPH oxidase in rabbit proximal tubular epithelial cells. Proc Natl Acad Sci USA 1997;94:3771-3776.
89. Diamond JR: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl 1991;31:S29-S34.
90. Wolf G, Ziyadeh FN, Zahner G, Stahl RA: Angiotensin II is mitogenic for cultured rat glomerular endothelial cells. Hypertension 1996;27:897-905.
91. Wolf G, Neilson EG: Angiotensin II induces cellular hypertrophy in cultured murine proximal tubular cells. Am J Physiol 1990;259:F768-F777.
92. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993;92:1366-1372.
93. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-2437.
94. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
95. Peters H, Border WA, Noble NA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570-1580.
96. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewski J, Caron RJ, Wenzel U, Zahner, G, Helmchen U, Stahl RA: Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor. J Clin Invest 1997;100:1047-1058.
97. Pupilli C, Lasagni L, Romagnani P, Bellini F, Mannelli M, Misciglia N, Mavilia C, Vellei U, Villari D, Serio M: Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J Am Soc Nephrol 1999;10:245-255.
98. Rabelink TJ, Bakris GL: The renin-angiotensin system in diabetic nephropathy: The endothelial connection. Miner Electrolyte Metab 1998;24:381-388.
99. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-581.
100. Remuzzi A, Fassi A, Sangalli F, Malanchini B, Mohamed EI, Bertani T, Remuzzi G: Prevention of renal injury in diabetic MWF rats by angiotensin II antagonism. Exp Nephrol 1998;6:28-38.
101. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
102. Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, Saito T, Abe K: Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995;13:97-103.
103. Kreisberg JI, Radnik RA, Ayo SH, Garoni J, Saikumar P: High glucose elevates c-fos and c-jun transcripts and proteins in mesangial cell cultures. Kidney Int 1994;46:105-112.
104. Ray PE, Bruggeman LA, Horikoshi S, Aguilera G, Klotman PE: Angiotensin II stimulates human fetal mesangial cell proliferation and fibronectin biosynthesis by binding to AT1 receptors. Kidney Int 1994;45:177-184.
105. Singh R, Alavi N, Singh AK, Leehey DJ: Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999;48:2066-2073.
106. Irani K: Oxidant signaling in vascular cell growth, death, and survival - A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-183.
107. Halliwell B: The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993;23(suppl 1):118-126.
108. Morgan BJ, Lyson T, Scherrer U, Victor RG: Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991;18:458-466.
109. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: Emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153-163.
110. Kihara M, Yabana M, Toya Y, Kobayashi S, Fujita T, Iwamoto T, Ishigami T, Umemura S: Angiotensin II inhibits interleukin-1 beta-induced nitric oxide production in cultured rat mesangial cells. Kidney Int 1999;55:1277-1283.
111. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.